SavedAdd your journal

Journals / Retina-Vitreus / 2011 / Cilt: 19 - Sayı: 4

The results of intravitreal ranibizumab injection for choroidal neovascularization from causes other than age-related macular degeneration

Yaşa bağlı maküla dejeneresansı dışı nedenlerle gelişen koroid neovaskülarizasyonlarında intravitreal ranibizumab enjeksiyonu sonuçları

Yeşim GEDİK OĞUZ
Figen BATIOĞLU
Emin ÖZMERT
Pages
231–236
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Short term results of intravitreal ranibizumab injection for CNV from causes other than AMD seem to be a safe and effective method but larger series, longer term studies are needed to determine the effectiveness of the long-term.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy of intravitreal ranibizumab injection in choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD).
📊
Key Findings & Data:Materials and Methods: We retrospectively reviewed the medical records of 23 eyes of 19 patients who were diagnosed with CNV secondary to causes other than AMD and treated with intravitreal ranibizumab injection during May 2006 and June 2010 at Ankara University Department of Ophthalmology.
💡
Conclusion & Impact:Conclusion: Short term results of intravitreal ranibizumab injection for CNV from causes other than AMD seem to be a safe and effective method but larger series, longer term studies are needed to determine the effectiveness of the long-term.
🔬Design:Review & Systematic Survey
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficacy of intravitreal ranibizumab injection in choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD). Materials and Methods: We retrospectively reviewed the medical records of 23 eyes of 19 patients who were diagnosed with CNV secondary to causes other than AMD and treated with intravitreal ranibizumab injection during May 2006 and June 2010 at Ankara University Department of Ophthalmology. Ranibizumab injections were performed at intervals of 4 weeks as monotherapy and Best Corrected Visual Acuity (BCVA), fundus examination, optical coherence tomography (OCT) and fundus angiography (FA) findings were retrospectively reviewed at each visit. Results: 10 patients were male (52.6%), 9 were female (47.4%). The mean age was 46.37±18.7 (21-84). Mean follow-up was 16.8±7.9 (2-34) months. 6 eyes (26.10%) had degenerative myopia, 5 eyes (21.70%) had angioid streaks, 4 eyes (%17.40) had Best vitelliform dystrophy and 8 eyes (34.80%) had idiopathic CNV. The mean number of injections were 4±2.8 in eyes with degenerative myopia, 2.8±0.44 in eyes with angioid streaks, 2.75±1.25 in eyes with Best vitelliform dystrophy and 2.12±0.99 in eyes with idiopathic CNV. The mean BCVA before and after injection were 1.45±0.73 and 1.00±0.50 logMAR (p>0.05) in eyes with degenerative myopia, 0.44±0.31 and 0.20 ±0.18 logMAR (p>0.05) in eyes with angioid streaks, 0.92±0.71 and 0.22±0.26 logMAR (p>0.05) in eyes with Best vitelliform dystrophy, 0.47±0.36 and 0.22±0.40 (p<0.0125) logMAR in eyes with idiopathic CNV. After the treatment, the numerical increase in BCVA levels were found in all diagnostic groups, but this increase was statistically significant only in eyes with idiopathic CNV group due to high number of cases compared with other groups.Subretinal/intraretinal fluid decreased or disappeared on OCT scans in accordance with the increase in BVCA. Conclusion: Short term results of intravitreal ranibizumab injection for CNV from causes other than AMD seem to be a safe and effective method but larger series, longer term studies are needed to determine the effectiveness of the long-term.

Özet

Amaç: Yaşa bağlı maküla dejeneresansı (YBMD) dışı nedenlerle gelişen koroid neovaskülarizasyonlarında (KNV) intravitreal ranibizumab (Lucentis) enjeksiyonunun sonuçlarını değerlendirmek. Gereç ve Yöntem: Ankara Üniversitesi Tıp Fakültesi Göz Hastalıkları AD Retina Bölümü’nde Mayıs 2008-Haziran 2010 tarihleri arasında YBMD dışı nedenlere ikincil KNV tanısı almış ve intravitreal ranibizumab enjeksiyonu uygulanmış olguların dosyaları geriye dönük olarak incelendi. Çalışmaya 19 hastanın 23 gözü dahil edildi. Ranibizumab enjeksiyonu tek tedavi olarak 4 hafta aralarla uygulandı. Olguların tedavi öncesindeki ve takiplerindeki en iyi düzeltilmiş görme keskinlikleri (EDGK), fundus muayeneleri, Optik koherens tomografi (OKT) ve fundus anjiografi (FA) bulguları geriye dönük olarak değerlendirildi. Bulgular: Hastaların 10’u erkek (%52.6), 9’u kadındı (%47.4). Yaş ortalaması 46.37±18.7 (21-84) idi. Ortalama takip süresi 16.8±7.9 (2-34) aydı. Gözlerin 6’sı (%26.10) dejeneratif miyopi, 5’i (%21.70) angioid streaks, 4’ü (%17.40) Best vitelliform distrofi, 8’i (%34.80) idyopatik KNV idi. Ortalama enjeksiyon sayısı dejeneratif miyopili gözlerde 4±2.82, angioid streaksli gözlerde 2.8±0.44, Best vitelliform distrofili gözlerde 2.75±1.25, idyopatik KNV’li gözlerde 2.12±0.99 idi. Tedavi öncesi ve sonrası ortalama EDGK’leri sırasıyla dejeneratif miyopili gözlerde 1.45±0.73 logMAR ve 1.00±0.50 logMAR (p>0.05), angioid streaksli gözlerde 0.44±0.31 ve 0.20±0.18 logMAR (p>0.05), Best vitelliform distrofili gözlerde 0.92±0.71 ve 0.22±0.26 logMAR (p>0.05), idyopatik KNV’li gözlerde 0.47±0.36 ve 0.22±0.40 logMAR (p<0.0125) olarak saptandı. Tedavi sonrası EDGK dü-zeylerinde sayısal artış tüm tanı gruplarında saptanırken bu artış sadece hasta sayısının diğer gruplara göre daha fazla olduğu idyopatik KNV’li gözlerde istatistiksel olarak anlamlı bulundu. EDGK düzeylerindeki artışa paralel olarak tedavi sonrası OKT’lerde, tedavi öncesine göre subretinal/intraretinal sıvı düzeylerinde azalma veya kaybolma saptandı. Sonuç: YBMD dışı KNV olgularında intravitreal ranibizumab tedavisi erken dönemde görme stabi-lizasyonu ve artışı yönünden güvenli ve etkili bir tedavi yöntemidir fakat uzun süreli etkinliğinin be-lirlenmesi için daha geniş serilerle, daha uzun süreli çalışmalara ihtiyaç vardır.

🔖

Cite This Article

OĞUZ, Y. G., BATIOĞLU, F., ÖZMERT, E. (2011). The results of intravitreal ranibizumab injection for choroidal neovascularization from causes other than age-related macular degeneration. Retina-Vitreus, Cilt: 19 - Sayı: 4, 231–236. https://ajindex.com/articles/307925

References (13)

  1. Gass JDM.: Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, ed 4. St. Louis, Mosby. 1997
  2. K.B. Freund, L.A. Yannuzzi and J.A. Sorenson.: Age-related macular degeneration and choroidal neovascularization, Am J Ophthalmol. 1993;115:786-791
  3. Z. Cui, H. Kimura and C. Spee et al.: Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate, Graefes Arch Clin Exp Ophthalmol. 2000;238:326-333
  4. T. Ishibashi, Y. Hata and H. Yoshikawa et al.: Expression of vascular endothelial growth factor in experimental choroidal neovascularization, Graefes Arch Clin Exp Ophthalmol. 1997;235:159-167
  5. G. Martin, G. Schlunck, L.L. Hansen et al.: Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium, Graefes Arch Clin Exp Ophthalmol. 2004;242:321-326
  6. Eye Diseases Prevalence Research Group.: Prevalence of age-related macular degeneration in the United States, Arch Ophthalmol. 2004;122:564-572
  7. Verteporfin in Photodynamic Therapy (VIP) Study Group.: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial VIP report no. 3, Ophthalmology. 2003;110:667-673
  8. Submacular Surgery Trials Research Group.: Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I: Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST report no. 9, Arch Ophthalmol. 2004;122:1597-1611
  9. Macular Photocoagulation Study Group.: Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials, Arch Ophthalmol. 1991;109:1109-1114
  10. Ferrara N, Damico L, Shams N et al.: Development of ranibizumab, an anti -vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870
  11. Brown DM, Michels M, Kaiser PK, et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the anchor study. Ophthalmology. 2009;116:57-65
  12. Regillo CD, Brown DM, Abraham P et al.: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145:239-248
  13. Rosenfeld PJ, Brown DM, Heier JS et al.: Ra